Epic Sciences mission is to improve patient lives by enabling precision medicine and personalize treatments.
To accomplish our mission, we are using our proprietary circulating tumor cell (CTC) detection platform to develop predictive tests of therapy benefit. These tests will provide the necessary information to physicians, helping them guide treatment decisions to extend patient lives. These tests are being developed in our CAP/CLIA laboratory (CLIA ID: 05D2087488).
JUST RELEASED: AR-V7 as an indication for treatment selection
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncology. Advance Online Publication: June 4, 2016. DOI:10.1001/jamaoncol.2016.1828